NCT02509533

Brief Summary

To evaluate the VAC (Vacuum Assisted Closure) therapy in transplants of leg ulcers versus usual dressing method. The VAC Therapy system consists of:

  • A unit delivering a precise under atmospheric pressure, controlled and regulated in the wound site,
  • Consumables necessary for the implementation of the dressing,
  • Collecting tanks exudates with gel. VAC therapy is a system using negative pressure. It is known to be efficient into care of chronic wounds and ulcerous wounds by increasing the cicatrisation. This system is systematically used into the dermatology unit of the CHU of Saint-Etienne after transplants of leg ulcers, but no data confirms the interest of this method compared to usual dressing method. This study will provide this data.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
36

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2010

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2010

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2013

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2014

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

July 21, 2015

Completed
7 days until next milestone

First Posted

Study publicly available on registry

July 28, 2015

Completed
Last Updated

July 28, 2015

Status Verified

July 1, 2015

Enrollment Period

3.1 years

First QC Date

July 21, 2015

Last Update Submit

July 27, 2015

Conditions

Keywords

Vacuum Assisted Closure

Outcome Measures

Primary Outcomes (1)

  • Percentage of healing between VAC system and compresses for all types of leg ulcers

    Number of patients having a wound at least 50% of the grafted area between VAC system and compresses

    1 month after the transplant

Secondary Outcomes (9)

  • Percentage of healing between VAC system and compresses for all types of leg ulcers

    3 months after the transplant

  • Evolution of the pain by Analogic Visual Scale.

    day 0 : just before the transplant

  • Evolution of the pain by Analogic Visual Scale.

    day 1 : the day after the transplant

  • Evolution of the pain by Analogic Visual Scale

    Month 1

  • Quality of life questionnaire score.

    day 0 : just before the transplant

  • +4 more secondary outcomes

Study Arms (2)

V.A.C.® Therapy

EXPERIMENTAL

In this arm, investigators will use the V.A.C.® Therapy after a transplants of leg ulcers.

Device: V.A.C.®

usual dressing method (compresses)

ACTIVE COMPARATOR

In this arm, investigators will use the usual dressing method after a transplants of leg ulcers.

Device: dressing

Interventions

V.A.C.®DEVICE

Patients received V.A.C.® Therapy (KCI medical) after a transplants of leg ulcers.

V.A.C.® Therapy
dressingDEVICE

Patients received usual dressing method (compresses) after a transplants of leg ulcers

usual dressing method (compresses)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patient hospitalized into the dermatology unit
  • patient with an evolutive leg ulcer since more than 1 month
  • signed informed consent

You may not qualify if:

  • known allergy to one of dressings used in this study
  • patient with a non-treated osteomyelitis
  • patient with tumoral tissues into the wound
  • patient with raw organ or raw blood vessels
  • patient with an anticoagulation treatment with a potentially hemorrhagic curative dose
  • patient having hemostasis problems that can lead to hemorrhagic exudates

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU de SAINT-ETIENNE

Saint-Etienne, 42000, France

Location

MeSH Terms

Conditions

Leg Ulcer

Interventions

Bandages

Condition Hierarchy (Ancestors)

Skin UlcerSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Equipment and Supplies

Study Officials

  • Bruno LABEILLE, MD

    CHU de SAINT-ETIENNE

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 21, 2015

First Posted

July 28, 2015

Study Start

September 1, 2010

Primary Completion

October 1, 2013

Study Completion

March 1, 2014

Last Updated

July 28, 2015

Record last verified: 2015-07

Locations